Advertisement

Allergen Immunotherapy Extract Shortages and Their Effects on Clinical Care: A Work Group Report of the AAAAI Immunotherapy, Allergen Standardization and Allergy Diagnostics Committee

Published:November 26, 2021DOI:https://doi.org/10.1016/j.jaip.2021.10.057
      Allergen immunotherapy (AIT) is the only disease-modifying therapy indicated for treatment of allergic asthma, rhinitis, conjunctivitis, and Hymenoptera hypersensitivity. Manufacturing of the extracts used in AIT involve multistep complex processes as well as regulatory oversight. Furthermore, some source materials are vulnerable to unexpected events of nature. Given these circumstances, allergen extract supply can be disrupted with a potential to adversely impact patient care. A group of members from the American Academy of Allergy, Asthma, and Immunology (AAAAI) Immunotherapy, Allergy Standardization and Allergy Diagnostic Committee formed a workgroup to assess the frequency and effects of allergen extract shortages and associated factors. This workgroup developed a survey that was distributed to a random 20% of the AAAAI membership. In addition, the group also performed a review of the scientific literature on allergen extract supply and shortage. Based on the findings of the survey study and literature review, the workgroup reports frequency and extent of shortages, potential ways to improve communication with suppliers, and need for further guidance in patient care during times of shortage.

      Key words

      Abbreviations used:

      AAAAI (American Academy of Allergy, Asthma, and Immunology), ACAAI (American College of Allergy, Asthma, and Immunology), AIT (Allergen immunotherapy), SCIT (Subcutaneous immunotherapy), SLIT (Sublingual immunotherapy), VIT (Venom immunotherapy)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal

      Subscribe:

      Subscribe to The Journal of Allergy and Clinical Immunology: In Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lei D.K.
        • Saltoun C.
        Allergen immunotherapy: definition, indications, and reactions.
        Allergy Asthma Proc. 2019; 40: 369-371
        • Akdis M.
        • Akdis C.A.
        Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens.
        J Allergy Clin Immunol. 2014; 133: 621-631
        • Bousquet J.
        • Pfaar O.
        • Togias A.
        • Schünemann H.J.
        • Ansotegui I.
        • Papadopoulos N.G.
        • et al.
        2019 ARIA Care pathways for allergen immunotherapy.
        Allergy. 2019; 74: 2087-2102
        • Leatherman B.
        • Skoner D.P.
        • Hadley J.A.
        • Walstein N.
        • Blaiss M.S.
        • Dykewicz M.S.
        • et al.
        The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: provider practices and beliefs about allergen immunotherapy.
        Int Forum Allergy Rhinol. 2014; 4: 779-788
        • Ponda P.
        • Mithani S.
        • Kopyltsova Y.
        • Sison C.
        • Gupta P.
        • Bonagura V.R.
        Allergen immunotherapy practice patterns: a worldwide survey.
        Ann Allergy Asthma Immunol. 2012; 108 (454-9.e7)
        • Hauck P.R.
        • Williamson S.
        The manufacture of allergenic extracts in North America.
        Clin Rev Allergy Immunol. 2001; 21: 93-110
        • Codina R.
        • Lockey R.F.
        Pollen used to produce allergen extracts.
        Ann Allergy Asthma Immunol. 2017; 118: 148-153
        • Esch R.E.
        • Codina R.
        Fungal raw materials used to produce allergen extracts.
        Ann Allergy Asthma Immunol. 2017; 118: 399-405
        • Fernández-Caldas E.
        • Cases B.
        • El-Qutob D.
        • Cantillo J.F.
        Mammalian raw materials used to produce allergen extracts.
        Ann Allergy Asthma Immunol. 2017; 119: 1-8
        • Plunkett G.
        • Jacobson R.S.
        • Golden D.B.K.
        Hymenoptera venoms used to produce allergen extracts.
        Ann Allergy Asthma Immunol. 2017; 118: 649-654
        • Slater J.E.
        Standardized allergen vaccines in the United States.
        Clin Allergy Immunol. 2008; 21: 273-281
      1. US Food & Drug Administration. Injectable allergen extracts—standardized. Silver Spring. MD: FDA; 2019. Accessed March 23, 2021. https://www.fda.gov/vaccines-blood-biologics/allergenics/injectable-allergen-extracts-standardized

      2. US Food & Drug Administration. Allergen extract sublingual tablets. Silver Spring. MD: FDA; 2019. Accessed September 23, 2021. https://www.fda.gov/vaccines-blood-biologics/allergenics/allergen-extract-sublingual-tablets

        • Goodman R.E.
        • Chapman M.D.
        • Slater J.E.
        The allergen: sources, extracts, and molecules for diagnosis of allergic disease.
        J Allergy Clin Immunol Pract. 2020; 8: 2506-2514
        • Bilò M.B.
        • Martini M.
        • Berra D.
        • Scarpa A.
        • Losappio L.
        • Quercia O.
        • et al.
        Hymenoptera venom immunotherapy: how to safely switch to the same venom from a different manufacturer.
        J Investig Allergol Clin Immunol. 2018; 28: 205-208
        • Stoevesandt J.
        • Trautmann A.
        Lessons from times of shortage: interchangeability of venom preparations and dosing protocols.
        Allergy. 2019; 74: 1392-1395
        • Golden D.B.K.
        • Bernstein D.I.
        • Freeman T.M.
        • Tracy J.M.
        • Lang D.M.
        • Nicklas R.A.
        AAAAI/ACAAI joint venom extract shortage task force report.
        J Allergy Clin Immunol Pract. 2017; 5: 330-332
        • Nasser S.
        • Whyte A.F.
        • Durham S.R.
        • Krishna M.T.
        Switch-over from Pharmalgen to Alutard Bee and Wasp venom in the UK.
        Clin Exp Allergy. 2019; 49: 1645-1646
        • Ridolo E.
        • Martignago I.
        • Passalacqua G.
        • Mauro M.
        • Incorvaia C.
        Evaluation of the safety of a protocol for switching venom immunotherapy products.
        Ann Allergy Asthma Immunol. 2018; 120: 429-430
        • Meadows J.A.
        • Golden D.B.K.
        • Tracy J.
        • Reyes E.G.
        • Sublett J.
        Venom shortages.
        Ann Allergy Asthma Immunol. 2019; 123: 9-10
        • Meadows J.A.
        • Golden D.B.K.
        • Tracy J.
        • Reyes E.G.
        • Sublett J.
        Venom shortages.
        Ann Allergy Asthma Immunol. 2019; 123: 131-132
        • Korošec P.
        • Jakob T.
        • Harb H.
        • Heddle R.
        • Karabus S.
        • de Lima Zollner R.
        • et al.
        Worldwide perspectives on venom allergy.
        World Allergy Organ J. 2019; 12: 100067
        • Tracy J.M.
        • Golden D.B.K.
        Hymenoptera venom extracts in clinical practice.
        J Allergy Clin Immunol Pract. 2018; 6: 1856-1862
        • Carpenter T.
        • Craig T.J.
        • Jones R.A.
        • Shaeffer S.
        • Yoder M.
        Restarting venom immunotherapy after the recent venom extract shortage: our experience as a tertiary center.
        J Allergy Clin Immunol. 2018; 141: AB77
        • Wohlfarth J.A.
        • Peterson L.A.
        • Willoughby W.T.
        Commercial laboratory preparation of immunotherapy vials.
        Curr Opin Otolaryngol Head Neck Surg. 2001; 9: 186-192
        • Loftus P.A.
        • Wise S.K.
        Epidemiology of asthma.
        Curr Opin Otolaryngol Head Neck Surg. 2016; 24: 245-249
        • Singh K.
        • Axelrod S.
        • Bielory L.
        The epidemiology of ocular and nasal allergy in the United States, 1988-1994.
        J Allergy Clin Immunol. 2010; 126 (778-83.e6)
        • Deckers I.A.
        • McLean S.
        • Linssen S.
        • Mommers M.
        • van Schayck C.P.
        • Sheikh A.
        Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies.
        PLoS One. 2012; 7e39803
      3. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update [Erratum: J Allergy Clin Immunol 2009;123:1421; J Allergy Clin Immunol 2008;122:842; J Allergy Clin Immunol 2008;122:842].
        J Allergy Clin Immunol. 2007; 120: S25-85
        • Scadding G.W.
        • Calderon M.A.
        • Shamji M.H.
        • Eifan A.O.
        • Penagos M.
        • Dumitru F.
        • et al.
        Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial.
        JAMA. 2017; 317: 615-625
        • Land M.
        • Wang J.
        Complementary and alternative medicine use among allergy practices: results of a nationwide survey of allergists.
        J Allergy Clin Immunol Pract. 2018; 6 (95-8.e3)
        • Bingemann T.
        • Sharma H.
        • Nanda A.
        • Khan D.
        • Markovics S.
        • Sussman J.
        • et al.
        AAAAI Work Group Report: physician wellness in allergy and immunology.
        J Allergy Clin Immunol Pract. 2020; 8: 1224-1229